BCRX
BioCryst Pharmaceuticals, Inc.
10.88
+
0.12
1.12%
9 x 10.86
15 x 10.87
bid
ask
16696 @ 03:50 PM
10.88+0.00 (0.00%)
Bearish
29
Bullish
76
sentiment
10.33
day range
10.95
7.61
52 week range
19.99
Prev Close10.76
Open10.84
Low10.33
High10.95
Volume3.45M
Avg. Volume4.96M
Market Cap2.02B
Inst. Own71.62%
Beta2.51
Short Ratio6.64
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target17.45
50day MA9.60
200day MA13.40
^DJI
Dow Jones Industrial Average
31438.30
12:00 AM
-
62.40
0.20%
^IXIC
NASDAQ Composite
11524.60
12:00 AM
-
83.00
0.72%
^GSPC
S&P 500
3900.11
12:00 AM
-
11.63
0.30%
AAPL
141.98
+0.32 (0.23%)
Apple Inc.
141.66
1022 @ 03:50 PM
3 x 141.10
7 x 141.11
+
0.00
0.00%
GOOG
2338.00
+5.55 (0.24%)
Alphabet Inc.
2332.45
1 @ 03:50 PM
1 x 2329.99
1 x 2331.29
-
38.31
1.62%
AMZN
113.60
+0.38 (0.34%)
Amazon.com, Inc.
113.22
1 @ 03:50 PM
1 x 112.96
3 x 112.97
-
3.24
2.78%
MSFT
265.23
+0.34 (0.13%)
Microsoft Corporation
264.89
3 @ 03:50 PM
2 x 263.64
1 x 263.67
-
2.81
1.05%
BABA
118.82
+0.09 (0.08%)
Alibaba Group Holding Limited
118.73
1 @ 04:00 PM
1 x 117.00
1 x 120.30
+
1.11
0.94%
NFLX
189.14
+0.00 (0.00%)
Netflix, Inc.
189.14
49 @ 03:50 PM
1 x 188.15
1 x 188.22
-
1.71
0.90%
TSLA
735.81
+1.05 (0.14%)
Tesla, Inc.
734.76
14 @ 03:50 PM
1 x 732.31
1 x 732.66
-
2.36
0.32%
NVDA
168.97
+0.28 (0.17%)
NVIDIA Corporation
168.69
100 @ 03:50 PM
2 x 168.13
3 x 168.16
-
2.57
1.50%
AMD
86.25
+0.09 (0.10%)
Advanced Micro Devices, Inc.
86.16
500 @ 03:50 PM
3 x 86.06
12 x 86.08
-
0.92
1.06%
MU
58.95
+0.17 (0.29%)
Micron Technology, Inc.
58.78
389 @ 03:50 PM
4 x 58.71
2 x 58.72
+
0.34
0.58%
SPY
389.20
+0.61 (0.16%)
SPDR S&P 500 ETF Trust
388.59
1 @ 06:02 PM
13 x 388.80
5 x 388.87
-
1.49
0.38%
TQQQ
27.49
+0.17 (0.62%)
ProShares UltraPro QQQ
27.32
25 @ 03:50 PM
100 x 27.10
69 x 27.11
-
0.66
2.36%
BRK-A
414500.00
-3200.00 (0.77%)
Berkshire Hathaway Inc.
417700.00
11 @ 04:02 PM
13 x 412000.00
8 x 425555.00
+
299.00
0.07%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison | defenseworld.net • |
| BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX) | seekingalpha.com • |
| Stocks Rally as Major Indexes Look to End Losing Streaks | schaeffersresearch.com • |
| Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like | uk.sports.yahoo.com • |
| Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength? | zacks.com • |
| Why BioCryst Pharmaceuticals Topped the Market Today | fool.com • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-08-04 | 2022-06 | -0.36 | N/A | N/A | N/A |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform | |
| 2022-04-11 | B of A Securities | Downgrade | Buy | Neutral |
| 2022-04-11 | Oppenheimer | Upgrade | Outperform | |
| 2021-12-10 | Oppenheimer | Upgrade | Outperform | |
| 2021-11-04 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Blackrock Inc. | 14.10M | 229.30M | 7.60% |
| 2022-03-30 | Vanguard Group, Inc. (The) | 13.21M | 214.75M | 7.12% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 206.68M | 6.85% |
| 2022-03-30 | FMR, LLC | 8.41M | 136.82M | 4.53% |
| 2022-03-30 | State Street Corporation | 7.46M | 121.34M | 4.02% |
| 2022-03-30 | Pictet Asset Management SA | 5.11M | 83.04M | 2.75% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 85.54M | 2.83% |
| 2022-04-29 | Fidelity Select Portfolios - Biotechnology | 4.19M | 38.95M | 2.26% |
| 2022-04-29 | iShares Russell 2000 ETF | 3.96M | 36.81M | 2.14% |
| 2022-04-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.71M | 34.50M | 2.00% |
| 2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 38.83M | 1.29% |
| 2022-03-30 | Vanguard Small-Cap Index Fund | 2.25M | 36.59M | 1.21% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Another day another disappointment
-
This is sad. Only news I see is July 3 changed to a hold
-
I’m still waking up, but so far I see no news on this one today. I see lots of news on others tho. I’ll hope for the best.
-
Some people say possibly $200, I could live with that.
-
How much can this stock realistically rise? I’ve read here anywhere from $25-200. I’ve done the math on all. 🤔🤑
-
Such a tease. Maybe next 2 weeks?
-
Maybe next week. Oh well
-
Everything Green but BCRX News please!
-
What the heck is going on? They manipulate it constantly day in and day out.
-
BioBoom have you nothing better to do than kick people down? Is that what makes you happy, really?
-
Selling at cost if I make it, will rebuy at the dip. This is not exploding anytime soon. Feeling done.
-
Something is very wrong with this picture. Giving this a 2 week deadline.
-
Still no news and dragging on. More of the same.
-
To Alan. Have you ever seen this before where a stock is majority institute owned and it’s manipulated like this? Ive only been in trading under a year. Just trying to learn. Tysm
-
Is bcrx The Sleeping Giant ? Why is there not one bit of news? It’s in a coma.
-
Today may not be the day. I was unhappy with this stock before but holding out hope based on the hints of better days. Not selling and might buy more on the dips. GL to all.
-
Order in for 4.78 let’s see if the line grabs it.
-
Fishing Line in the water
-
Awhile back it was posted recent job positions in bcrx does a one have that info to post again? Ty
-
@Bioboom what is your interest in this stock and why do you keep warning us about it? Are you a professional stock trader? Curious.
-
BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX)
seekingalpha.com • -
Stocks Rally as Major Indexes Look to End Losing Streaks
schaeffersresearch.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com • -
BioCryst Short-Sellers Lose Control
seekingalpha.com • -
BioCryst Shares Slide As Reddit-Induced Rally Peters Out
benzinga.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com •
